annb0t
Top 20
Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea market and valuations appear attractive at current levels, with a strong balance sheet position and the highest ROIC across the firmâs Australian Healthcare industry sector coverage, the analyst tells investors.
Light Up your Portfolio with Spark:
Easily identify stocks' risks and opportunities. Disc...
>>> Read more: ResMed initiated with an Overweight at Morgan Stanley
Light Up your Portfolio with Spark:
Easily identify stocks' risks and opportunities. Disc...
>>> Read more: ResMed initiated with an Overweight at Morgan Stanley
